LeMaitre Vascular reported strong Q1 2025 results with sales up 12% organically, driven by growth in grafts and carotid shunts. The company increased its full-year sales guidance and highlighted its strategic optionality due to a strong cash position.
Sales increased by 12% to $59.9 million, with organic growth at 13%.
Gross margin improved to 69.2%, up 60 basis points from the prior year.
Operating income grew 6% to $12.6 million, resulting in an operating margin of 21%.
Diluted earnings per share rose 10% to $0.48, and cash increased sequentially to $302.5 million.
LeMaitre Vascular increased its full-year 2025 sales guidance and provided Q2 2025 guidance, reflecting continued positive momentum and strategic flexibility.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance